Document is current
Any future updates will be listed below
-
Authors
Tepel, Martin
Alkaff, Firas F.
Kremer, Daan
Bakker, Stephan J. L.
Thaunat, Olivier
Nagarajah, Subagini
Saleh, Qais
Berger, Stefan P.
van den Born, Jacob
Krogstrup, Nicoline V.
Nielsen, Marie B.
Nørregaard, Rikke
Jespersen, Bente
Sparding, Nadja
Genovese, Federica
Karsdal, Morten A.
Rasmussen, Daniel G. K.
- License Information
-
More Information
Article History
Received: 27 October 2021
Accepted: 15 February 2022
First Online: 8 March 2022
Competing interests
: NS, FG, MAK, and DGKR are full-time employees at Nordic Bioscience and FG MAK and DGKR hold stocks. Nordic Bioscience is a privately-owned, small–medium-sized enterprise partly focused on the development of biomarkers and owns the patent for the ELISA used to measure endotrophin levels. No authors received fees, bonuses, or other benefits for the work described in the manuscript, and Nordic Bioscience did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
